Your Mission, Our Support
Working with you to bring transformative therapies to patients.
With You at Every Step
Wherever you are in the journey, we’re here with the expert guidance and support to help you move your mission forward.
Our Expertise in AAV Gene Therapy Development
Partner with our experts to define and refine your AAV therapy today.
Research-Grade Material for Proof-of-Concept Studies
We’ve helped others navigate this path and our team is here to help guide you forward.
Comprehensive Regulatory Support
Here to help shape your regulatory strategy for success and impact, with comprehensive support as you prepare for every milestone.
Proof-of-concept
Start with Blaze Research-Grade Production
Blaze is our research-grade AAV production offering at 1–40L, designed for early-stage discovery work like generating material for proof-of-concept studies and evaluating vector manufacturability.
guiding what’s next
Support Your Next Step in AAV Production
Navigating the complexities of AAV development and manufacturing is critical to bringing effective therapies to patients. Our comprehensive manufacturing services and expert support are designed to help guide you through every step of the process.
Forge Your Path
Let’s talk about how we can help advance your therapy to patients.
Hot off the Forge
-
Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing
Building on an AAV manufacturing partnership with new plasmid production, Forge’s end-to-end manufacturing services will help to advance Ray’ gene therapy for patients living with retinitis pigmentosa and other blinding…
-
Myrtelle and Forge Biologics Announce Viral Vector and Plasmid DNA cGMP Manufacturing Partnership
The partnership will help advance Myrtelle’s novel gene therapy for monogenic hearing loss, Myr-201, into clinical trials for patients with autosomal recessive deafness 8 (DFNB8).
-
Forge Biologics Fuels Gene Therapy Manufacturing Engine with Launch of Plasmid DNA Manufacturing Services to Support AAV Clients
New offering complements Forge’s existing AAV process development, analytical development, cGMP manufacturing, and automated final fill capabilities.
-
Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership
Strategic alliance will help advance the development and manufacturing of SGT-003, Solid’s next generation gene therapy program for Duchenne.